Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
16.15
-0.34 (-2.06%)
Nov 17, 2026, 3:04 PM CST
SHE:300204 Revenue
Staidson (Beijing) BioPharmaceuticals had revenue of 54.29M CNY in the quarter ending September 30, 2026, a decrease of -1.19%. This brings the company's total for the last twelve months to 186.88M, down -23.53% year-over-year. In the year 2025, Staidson (Beijing) BioPharmaceuticals had annual revenue of 220.23M, down -32.20%. That makes Staidson (Beijing) BioPharmaceuticals the 31,837th largest company in the world by revenue and 5,031st in China.
Revenue (ttm)
186.88M
Revenue Growth
-23.53%
P/S Ratio
47.97
Revenue / Employee
380.61K
Employees
491
Market Cap
8.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.23M | -104.58M | -32.20% |
| Dec 31, 2024 | 324.82M | -39.36M | -10.81% |
| Dec 31, 2023 | 364.18M | -184.81M | -33.66% |
| Jan 1, 2023 | 548.99M | -35.30M | -6.04% |
| Dec 31, 2021 | 584.29M | 159.08M | 37.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.74B |
| Pacific Shuanglin Bio-pharmacy | 2.42B |
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.16B |
| Shanghai Medicilon | 1.54B |
| Liaoning Chengda Biotechnology | 1.34B |
| Shanghai OPM Biosciences | 822.13M |
| Chongqing Genrix Biopharmaceutical | 800.98M |